Methods and compositions for the expression of constitutively active RAP1A from a VMD2 promoter
AssigneesUniversity of Utah Research Foundation, University of Flordia Research Foundation, Inc.
InventorsMary Elizabeth Hartnett, Haibo Wang, William Hauswirth, Vince Chiodo
Life of this patent
Estimating the term…
Abstract
Disclosed are nucleic acid constructs comprising a nucleic acid sequence encoding a vitelliform macular dystrophy-2 (VMD2) promoter operably linked to a nucleic acid sequence encoding Rap1a. Disclosed are vectors comprising the nucleic acid constructs disclosed herein. Disclosed are compositions comprising the disclosed nucleic acid constructs or vectors. Also disclosed are methods of treating a subject having age-related macular degeneration comprising administering one or more of the disclosed nucleic acid constructs, vectors, or compositions to a subject in need thereof.
Claims14
A nucleic acid construct comprising a nucleic acid sequence encoding a human vitelliform macular dystrophy-2 (VMD2) promoter operably linked to a nucleic acid sequence encoding active Rap1a, wherein the nucleic acid sequence encoding active Rap1a is a constitutively active Rap1a (CARap1a), wherein the CARap1a comprises the sequence of SEQ ID NO:2, wherein the human VMD2 promoter comprises the sequence of SEQ ID NO:
- 1.
Dependencies are inferred from the claim text.